首页> 美国政府科技报告 >Testing ER-Beta Agonist Synergy with B7-H1 and mTOR Inhibitors as Novel and Effective Treatments for Ovarian Cancer.

【24h】

Testing ER-Beta Agonist Synergy with B7-H1 and mTOR Inhibitors as Novel and Effective Treatments for Ovarian Cancer.

机译：测试ER-Beta激动剂协同作用与B7-H1和mTOR抑制剂作为卵巢癌的新型和有效治疗。

获取原文

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Curiel, T.; Vadlamudi, R.;
展开▼
作者单位

展开▼
年度 2016
页码 1-8
总页数 8
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer. [J] . Julie M Madden, Kelly L Mueller, Aliccia Bollig-Fischer, Breast cancer research and treatment. . 2014,第2期

机译：在三阴性乳腺癌中，EGFR和mTOR抑制剂的协同作用需要降低eIF4B的磷酸化水平。
2. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer. [J] . Julie M Madden, Kelly L Mueller, Aliccia Bollig-Fischer, Breast cancer research and treatment. . 2014,第2期

机译：在三重阴性乳腺癌中，EGFR和MTOR抑制剂协同措施需要耗尽EIF4B的磷酸化。
3. PI3K/AKT/mTOR inhibitors in ovarian cancer. [J] . Mazzoletti M, Broggini M Current medicinal chemistry . 2010,第36期

机译：PI3K / AKT / mTOR抑制剂在卵巢癌中的作用。
4. Simulations of the EGFR - KRAS - MAPK Signalling Network in Colon Cancer. Virtual Mutations and Virtual Treatments with Inhibitors Have More Important Effects Than a 10 Times Range of Normal Parameters and Rates Fluctuations [C] . Nicoletta Castagnino, Lorenzo Tortolina, Roberto Montagna, International Meeting on Computational Intelligence Methods for Bioinformatics and Biostatistics . 2010

机译：EGFR - KRAS - MAPK信号网络在结肠癌中的模拟。具有抑制剂的虚拟突变和虚拟处理具有比正常参数范围的10倍的更重要的效果和速率波动
5. Chlor-amidine, a novel PAD inhibitor, as an effective drug for the treatment of ulcerative colitis and prevention of colorectal cancer. [D] . Witalison, Erin. 2016

机译：氯-，一种新型的PAD抑制剂，是治疗溃疡性结肠炎和预防结直肠癌的有效药物。
6. Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma [O] . Rong Wu, Tom C. Hu, Alnawaz Rehemtulla, -1

机译：卵巢剂腺癌腺癌小鼠模型中PI3K / AKT / MTOR信号抑制剂的临床前测试
7. Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma [O] . Rong Wu, Tom C. Hu, Alnawaz Rehemtulla, 2011

机译：卵巢剂腺癌腺癌小鼠模型中PI3K / AKT / MTOR信号抑制剂的临床前测试
8. Testing ER-Beta Agonist Synergy with B7-H1 and mTOR Inhibitors as Novel and Effective Treatments for Ovarian Cancer. [R] . Curiel, T., Vadlamudi, R. 2016

机译：测试ER-Beta激动剂协同作用与B7-H1和mTOR抑制剂作为卵巢癌的新型和有效治疗。

Testing ER-Beta Agonist Synergy with B7-H1 and mTOR Inhibitors as Novel and Effective Treatments for Ovarian Cancer.

著录项

引文网络

相似文献

相关主题

期刊订阅